Shin Poong Pharm.Co.,Ltd. manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products. It also provides active pharmaceutical ingredients; Pyramax, an anti-malarial drug; drugs for treating hypercholesterolemia, knee osteoarthritis and shoulder periarthritis, and surgical adhesion barrier; and over the counter products. The company also exports its products to approximately 50 countries. Shin Poong Pharm.Co.,Ltd. was founded in 1962 and is headquartered in Seoul, South Korea.
Revenue of Shin Poong Pharm.Co.,Ltd. (019170.KS)
Revenue in 2023 (TTM): $143.16 M
According to Shin Poong Pharm.Co.,Ltd.'s latest financial reports the company's current revenue (TTM) is $143.16 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Shin Poong Pharm.Co.,Ltd.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $143.16 M | $56.21 M | $-26,502,377 | $-38,209,857 | $-40,986,549 |
| 2022 | $149.64 M | $55.75 M | $-15,889,248 | $-24,868,130 | $-25,245,133 |
| 2021 | $135.3 M | $55.33 M | $911.42 K | $-6,424,563 | $-8,240,876 |
| 2020 | $141.39 M | $54.72 M | $15.04 M | $5.96 M | $3.58 M |
| 2019 | $135.65 M | $54.47 M | $16.35 M | $5.09 M | $3.81 M |
| 2018 | $133.98 M | $54.26 M | $13.67 M | $3.71 M | $2 M |
| 2017 | $132.27 M | $57.29 M | $12.86 M | $1.22 M | $646.98 K |
| 2016 | $138.81 M | $62.87 M | $7.38 M | $-2,647,693 | $-13,292,707 |
| 2015 | $140.1 M | $61.98 M | $13.93 M | $1.55 M | $1.06 M |
| 2014 | $157.5 M | $72.19 M | $23.1 M | $9.66 M | $2.39 M |
| 2013 | $154.41 M | $68.29 M | $26.02 M | $14.07 M | $3.89 M |
| 2012 | $158.13 M | $63.91 M | $22.92 M | $12.91 M | $10.28 M |
| 2011 | $164.23 M | $73.74 M | $32.9 M | $22.52 M | $17.78 M |
| 2010 | $165.92 M | $79.17 M | $37.38 M | $27.41 M | $15.54 M |
| 2009 | $155.33 M | $75.18 M | $31.51 M | $22.03 M | $15.05 M |
| 2008 | $134.51 M | $68.52 M | $23.12 M | $14.61 M | $8.62 M |
| 2007 | $118.63 M | $57.13 M | $18.38 M | $11.05 M | $6.32 M |